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Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer
patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has
been associated with response to anthracyclines. Limited information exists on the relationship of HER2/TOP2A gene
status in the presence of centromere 17 (CEP17) gain with outcome of patients treated with anthracycline-
containing adjuvant chemotherapy.
Methods: Formalin-fixed paraffin-embedded tumor tissue samples from 1031 patients with high-risk operable
breast cancer, enrolled in two consecutive phase III trials, were assessed in a central laboratory by fluorescence in
situ hybridization for HER2/TOP2A gene amplification and CEP17 gain (CEP17 probe). Amplification of HER2 and
TOP2A were defined as a gene/CEP17 ratio of >2.2 and ≥2.0, respectively, or gene copy number higher than 6.
Additionally, HER2, TopoIIa, ER/PgR and Ki67 protein expression was assessed by immunohistochemistry (IHC) and
patients were classified according to their IHC phenotype. Treatment consisted of epirubicin-based adjuvant
chemotherapy followed by hormonal therapy and radiation, as indicated.
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Results: HER2 amplification was found in 23.7% of the patients and TOP2A amplification in 10.1%. In total, 41.8% of
HER2-amplified tumors demonstrated TOP2A co-amplification. The median (range) of HER2, TOP2A and CEP17 gain
was 2.55 (0.70-45.15), 2.20 (0.70-26.15) and 2.00 (0.70-26.55), respectively. Forty percent of the tumors had CEP17
gain (51% of those with HER2 amplification). Adjusting for treatment groups in the Cox model, HER2 amplification,
TOP2A amplification, CEP17 gain and HER2/TOP2A co-amplification were not associated with time to relapse or time
to death.
Conclusion: HER2 amplification, TOP2A amplification, CEP17 gain and HER2/TOP2A co-amplification were not
associated with outcome in high-risk breast cancer patients treated with anthracycline-based adjuvant
chemotherapy.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12611000506998 and
ACTRN12609001036202
Keywords: HER2, TOP2A, TopoIIa, Prognostic factors, Predictive factors, Adjuvant chemotherapy, Anthracyclines,
Taxanes, Breast cancerBackground
Breast cancer is the most frequent non-skin malignancy
and the second leading cause of cancer death in American
and European women [1,2]. Adjuvant chemotherapy is ad-
ministered to most patients with high-risk operable breast
cancer, since it prolongs disease-free survival (DFS) and
overall survival (OS) [3]. Anthracyclines and taxanes are
considered to be two of the most efficient drugs in this
setting [4,5]. Despite intensive clinical research devoted
to the role of adjuvant chemotherapy, the majority of
patients do not benefit from its use and a small but
considerable percentage of them suffer from long-term
life-threatening toxicities, such as acute leukemia,
myelodysplasia or irreversible congestive heart failure
[6,7]. To select candidate patients for such aggressive
treatments, robust prognostic markers in human breast
cancer are needed. Investigators intensively evaluate well-
established oncogenes or chromosome aberrations, using
large tumor repositories, in an effort to widen their know-
ledge on the molecular mechanisms, gene interrelation-
ships or gene function underlying breast cancer.
It has long been established that breast cancer is often
characterized by gains or losses of specific chromo-
somes, leading to activation of oncogenes or inactivation
of tumor suppressor genes [8]. Chromosome 17 is the
second most gene-dense chromosome in the human
genome, housing important genes for breast cancer
pathophysiology, such as BRCA1, HER2, RAD51C,
RARA, TOP2A and TP53 [9]. Changes of chromosome
17 copy number (aneusomy) are extremely frequent in
breast cancer [10]. These chromosome aberrations
(reviewed in ref. [11]) are tightly linked to important cell
functions, such as proliferation, apoptosis, angiogenesis
and motility. Increased numbers of centromere 17 copies
are seen in 10% to 50% of breast tumors [12-14],
depending on the criteria used, and this is morecommon in tumors with HER2 gene amplification. How-
ever, it has to be stated that an increase in chromosome
17 signals seen with fluorescence in situ hybridization
(FISH) does not always correspond to true polysomy of
the whole chromosome, but may rather represent a focal
pericentromeric gain or partial polysomy [15]. Other
abnormalities of chromosome 17 include losses and
gains of genetic material in both the p and q arms, focal
copy number gains and losses and other structural
rearrangements [15,16]. Indeed, recent studies using differ-
ent techniques, such as comparative genomic hybridization
(CGH) [17,18], multiplex ligation-dependent probe
amplification (MLPA) [19], single nucleotide polymorph-
ism arrays (SNP arrays) [15], or FISH using alternative
chromosome 17 reference genes (RARA, TP53, SMS) [20]
suggested that true chromosome 17 polysomy is a rare
event in breast cancer. In fact, in most of the cases,
polysomy, as detected by FISH or chromogen in situ
hybridization (CISH), actually reflects a gain or amplifica-
tion in the pericentromeric region of the chromosome
[21]. For these reasons the term “CEP17 gain” instead of
“chromosome 17 polysomy”, is used here, referring to
its detection by the centromere 17 enumeration probe
(CEP17 probe).
CEP17 gain has been incriminated for the inconsisten-
cies seen in cases with HER2 gene amplification defined
by absolute gene copy numbers, versus gene amplifica-
tion defined by the ratio of HER2 gene copy number to
CEP17. Misclassification of HER2 gene status based on
dual-color FISH assays, due to CEP17 gain, may have
important therapeutic implications since a number of
patients considered being HER2-negative by the second
definition could be denied trastuzumab.
Importantly, recently published data from retrospect-
ively assessed (although prospectively collected) tumors,
by triple color FISH, from 1762 patients who participated
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suggested that CEP17 duplication was associated with
increased relapse-free and overall survival in patients
treated with an anthracycline compared to CMF [22].
The HER2 oncogene is located on the long arm of
chromosome 17 (17q12) [23]. HER2 amplification and/
or protein overexpression has been identified in 15% to
25% of invasive breast tumors [24] and is associated with
worse prognosis [25]. HER2 gene amplification has been
shown to predict benefit from the use of several chemo-
therapeutic agents, including anthracyclines and paclitaxel
[26,27]. Notably, a meta-analysis provided compelling
evidence that the use of anthracyclines benefits exclu-
sively those patients with HER2 amplification [28].
However, other investigators could not confirm these
data [29,30], suggesting that other genes, also located
on chromosome 17, may regulate anthracycline respon-
siveness [26].
One such gene is the topoisomerase II alpha gene
(TOP2A), which is located ~700 kb telomerically to
HER2 and encodes the alpha isozyme of the human
topoisomerase II. In general, topoisomerases are respon-
sible for transcription, replication and chromosome con-
densation and segregation during cell division [31,32].
TOP2A in particular is considered a molecular target for
anthracyclines and other chemotherapeutic agents [33,34].
The TOP2A gene is amplified in 30%-40% of the tumors
with HER2 gene amplification, while deletions are fre-
quently observed [35]. TOP2A gene amplification [36]
and, perhaps, topoisomerase II alpha (TopoIIa) protein
overexpression [37] may benefit high-risk breast cancer
patients treated with anthracyclines.
Information regarding the interaction of HER2/TOP2A
gene status in the presence of CEP17 gain with the out-
come of breast cancer patients is limited. This urged us
to investigate the prognostic role of HER2 and TopoIIa
protein expression, as well as HER2 and TOP2A gene
status along with CEP17 gain in a large cohort of breast
cancer patients. This is a prospective-retrospective study
as described by Simon [38], performed in the context of
two randomized, consecutively conducted, phase III
trials (HE10/97 and HE10/00) with epirubicin-based ad-
juvant chemotherapy with or without paclitaxel [39-42].
Methods
Clinical studies
The HE10/97 trial [39] was a randomized phase III trial
(ACTRN12611000506998) in patients with high-risk
node-negative or intermediate/high-risk node-positive
operable breast cancer, comparing four cycles of
epirubicin (E) followed by four cycles of intensified CMF
(E-CMF) with three cycles of E, followed by three cycles of
paclitaxel (T, TaxolW, Bristol Myers-Squibb, Princeton, NJ)
followed by three cycles of intensified CMF (E-T-CMF).All cycles were given every two weeks with G-CSF support.
Dose intensity of all drugs in both treatment arms was
identical, but cumulative doses and duration of chemother-
apy period differed. Totally, 595 eligible patients entered
the study in a period of 3.5 years (1997–2000).
The HE10/00 trial [40,41] was a randomized phase III
trial (ACTRN12609001036202), in which patients were
treated with E-T-CMF (exactly as in the HE10/97 trial)
or with four cycles of epirubicin/paclitaxel (ET) combin-
ation (given on the same day) every three weeks
followed by three cycles of intensified CMF every two
weeks (ET-CMF). By study design, the cumulative doses
and the chemotherapy duration were identical in the
two arms but dose intensity of epirubicin and paclitaxel
was double in the E-T-CMF arm. A total of 1086 eligible
patients with node-positive operable breast cancer were
accrued in a period of 5 years (2000–2005).
HER2-positive patients received trastuzumab upon
relapse, as previously described [43]. Treatment sched-
ules for the two studies, baseline characteristics and
clinical outcomes of both trials have already been
described in detail [39-42]. Primary tumor diameter,
axillary nodal status and tumor grade were obtained
from the pathology report. Clinical protocols were ap-
proved by local regulatory authorities, while the
present translational research protocol was approved
by the Bioethics Committee of the Aristotle University
of Thessaloniki School of Medicine. All patients
signed a study-specific written informed consent be-
fore randomization, which in addition to giving con-
sent for the trial allowed the use of biological material
for future research purposes.
Tissue microarray (TMA) construction
Formalin-fixed paraffin-embedded (FFPE) tumor tissue
samples from 1031 patients (61.3% of 1681 randomized
patients) were collected from both trials, retrospectively
in the first (HE10/97) and prospectively in the second
(HE10/00). The REMARK diagram [44] for the study is
shown in Figure 1. Hematoxylin-eosin stained sections
from the tissue blocks were reviewed by two experienced
breast cancer pathologists (M.B. and D.T.) and the most
representative tumor areas were marked for the con-
struction of the TMA blocks with the use of a manual
arrayer (Model I, Beecher Instruments, San Prairie, WI),
as previously described [45,46]. Each case was repre-
sented by 2 tissue cores, 1.5 mm in diameter, obtained
from the most representative areas of primary invasive
tumors or in some cases (9.6%) from synchronous axil-
lary lymph node metastases and re-embedded in 51
microarray blocks. Each TMA block contained 38 to 66
tissue cores from the original tumor tissue blocks, while
cores from various neoplastic, non-neoplastic and react-
ive tissues were also included, serving as controls for
58 blocks excluded
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Figure 1 REMARK diagram.
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inadequate on the TMA sections were re-cut from the
original blocks and these sections were used for protein
and gene analysis. Histological grade was evaluated
according to the Scarff, Bloom and Richardson system.
Immunohistochemistry (IHC)
Immunohistochemical labeling was performed according
to standard protocols on serial 2.5 μm thick sections
from the original blocks or the TMA blocks. All cases
were also stained for vimentin (clone V9, Dako,
Glostrup, Denmark) and cytokeratin 8/18 (clone 5D3,
Novocastra™, Leica Biosystems, Newcastle, U.K), which
were used as control stains for tissue immunoreactivity
and fixation, as well as identification of tumor cells.
Tissue samples negative for the above antibodies were
excluded from the study. To assure optimal reactivity,
immunostaining was applied 7 to 10 days after section-
ing at the Laboratory of Molecular Oncology of the
Hellenic Foundation for Cancer Research, Aristotle
University of Thessaloniki School of Medicine. The stain-
ing procedures for HER2 (A0485 polyclonal antibody,
Dako), estrogen receptor (ER, clone 6 F11, Novocastra™,
Leica Biosystems), progesterone receptor (PgR, clone 1A6,
Novocastra™, Leica Biosystems) and Ki67 (clone MIB-1,
Dako) were performed using a Bond Max™ autostainer
(Leica Microsystems, Wetzlar, Germany), as previouslydescribed [47]. TopoIIa protein expression was evaluated
using the KiS1 monoclonal antibody (Dako), as previously
described [48] with slight modifications (antibody dilution:
1:200; detection system: Envision™, Dako).
Interpretation of the IHC results
The evaluation of all IHC sections was done by two ex-
perienced breast cancer pathologists (M.B. and A.B.),
blinded as to the patients’ clinical characteristics and
survival data, according to existing established criteria,
as previously described [43]. Briefly, HER2 protein
expression was scored in a scale from 0 to 3+, the latter
corresponding to uniform, intense membrane staining
in >30% invasive tumor cells [49]; ER and PgR were
evaluated using the Histoscore method (max score:
400) and were considered positive if staining was
present in ≥1% of tumor cell nuclei [50]; for Ki67, the
expression was defined as low (<14%) or high (≥14%)
based on the percentage of stained/unstained nuclei
from the tumor areas [51]; and, for TopoIIa immuno-
staining, a tumor was considered to be positive if mod-
erate to intense nuclear staining was detected in >5% of
tumor cells [52]. The mean percentage of stained cells
from the two cores was calculated, while in cases with
different intensities, the higher intensity score obtained
from the two cores was used. If one of the tissue cores
was lost or damaged the overall score was determined
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were used, the entire tumor area was evaluated.
Fluorescence in situ hybridization (FISH)
TMA sections or whole sections (5 μm thick) were cut for
FISH analysis, using the ZytoLightW SPEC HER2/TOP2A/
CEP17 triple-color probe kit (ZytoVision, Bremerhaven,
Germany). The FISH was performed according to the
manufacturer’s protocol with minor modifications. Four
carcinoma cell lines (MDA-MB-231, MDA-MB-175,
MDA-MB-453 and SK-BR-3) from the Oracle HER2
Control Slide (Leica Biosystems), with a known HER2
gene status, were also used as a control for the FISH
assays and analyzed for HER2 and TOP2A genomic status.
For all probes, sequential (5 planes at 1.0 μm) digital
images were captured using the Plan Apo VC 100x/1.40
oil objective (Nikon, Japan) using specific filters for each
probe. The resulting images were reconstructed using
specifically developed software for cytogenetics (XCyto-
Gen, ALPHELYS, Plaisir, France). Processed sections
were considered eligible for FISH evaluation according
to the ASCO/CAP criteria [49]. For the evaluation of
HER2/TOP2A/CEP17 status, non-overlapping nuclei
from the invasive part of the tumor were randomly
selected, according to morphological criteria using DAPI
staining, and scored (M.B and E.T). The virtual slides of
HER2, ER or PgR stains, created as previously described
[47], were used for selecting the invasive part of the
tumor in each TMA. Twenty tumor nuclei were counted
according to Press et al. [53]. The HER2 gene was con-
sidered to be amplified when the HER2/CEP17 ratio
was >2.2 [49], or the mean HER2 copy number was >6
[54] and deleted when the ratio was <0.8.
The TOP2A gene was considered to be amplified when
the TOP2A/CEP17 ratio was ≥2.0 and deleted when the
ratio was <0.8 [36]. Cases with ≥3 CEP17 hybridization
signals detected in >30% of counted nuclei were classi-
fied as CEP17 gain [55]. Re-classification of CEP17 gain
was performed for the current analysis in comparison to
the previous report [56].
In cases with ratios at or near the cut-off (1.8-2.2 for
amplifications and 0.7-0.9 for deletions), additional 20 or
40 nuclei were counted and the ratio was recalculated.
In cases with a borderline ratio at 60 nuclei, additional
FISH assays were performed in whole sections [57]. In
addition, tumors were classified according to the
number of gene copies as normal (≤4 copies), low gain
(4–6 copies) or high gain (>6 copies) tumors. The first
category included tumors with possible gene losses, dip-
loid, or with replicated DNA; the second, tumors with
possible polysomy for the gene of interest; and, the third,
tumors with unequivocal gene amplification. All primary
image data of the TMA and whole tumor sections have
been digitally scanned and made publicly available at:http://www.hecog-images.gr/HER2/TOP2A/CEN17/
FISH_HE10/97_HE10/00.Statistical analysis
Categorical data are presented as numbers and corre-
sponding percentages, while continuous data are presented
as median and range values. The Fisher’s exact or Pearson
chi-square tests were used for group comparison of
categorical data, while for continuous data the Mann–
Whitney test was used. DFS was defined as the time inter-
val from study entry to first locoregional recurrence, first
distant metastasis, contralateral breast cancer, secondary
neoplasm, death from the disease, or death from any cause,
whichever occurred first [58]. OS was measured from
study entry until death from any cause. Surviving patients
were censored at the date of last contact. Kaplan-Meier
curves and log-rank tests were used for comparing time to
event distributions.
Cox proportional hazard regression analyses, adjusted
for treatment, were performed for the examined
markers, as well as for the combination of HER2/TOP2A
gene status to assess prognostic significance on DFS and
OS. In multivariate analysis, a backward selection pro-
cedure with p > 0.10 as a removal criterion based on the
likelihood ratio test was performed to identify significant
clinicopathological variables among the following: age
(≥50 vs. <50), treatment group (E-CMF vs. ET-CMF
vs. E-T-CMF), menopausal status (postmenopausal vs.
premenopausal), histological grade (III-undifferentiated vs.
I-II), Ki67 protein expression (high vs. low), tumor size
(>5 cm vs. 2 to 5 cm vs. <2 cm), number of positive axil-
lary nodes (≥4 vs. 0–3), ER/PgR status (positive vs. nega-
tive), adjuvant hormonotherapy (yes vs. missing vs. no)
and type of operation (breast-conserving surgery vs. modi-
fied radical mastectomy). Treatment group and the exam-
ined markers were included in the final model, in order to
examine whether they added independent prognostic
information to the model containing the significant clini-
copathological parameters.
The results of this study are presented according to
reporting recommendations for tumor marker prognostic
studies [44]. No adjustments for multiple comparisons were
done. Statistical analyses were performed using the follow-
ing statistical software: SPSS for Windows (version 15.0,
IBM Corporation, Armonk, NY) and SAS for Windows
(version 9.3, SAS Institute Inc., Cary, NC).Results
A total of 1031 patients with available FFPE tumor tissue
blocks were included in the analysis at a median follow-
up of 106 months (updated in March 2012). Results at
median follow-up of 92 months were presented at the
2011 San Antonio Breast Cancer Symposium [56].
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in Table 1. The majority of the patients were postmeno-
pausal (53.1%), had ≥4 positive nodes (60.4%) and tumors
of ductal histology (77.6%), while approximately half of the
patients had tumors of high grade (50.2%). The basic clini-
copathological characteristics were similar between patients
with and without available tissue blocks in each study,
except for the number of positive nodes, radiotherapy treat-
ment and histological grade (above II) (Additional file 1:Table 1 Selected patient and tumor characteristics
N = 1031
Age in years
Median (range) 52.5 (22–79)
Number of positive nodes































Hormonal therapy 799 (77.5)
MRM, modified radical mastectomy; N, number.Table S1). Patients with available tissue blocks had a higher
incidence of ≥4 positive nodes (p = 0.022 and p = 0.027 for
HE10/97 and HE10/00, respectively). This fact was prob-
ably reflected in the corresponding more frequent use of
radiotherapy treatment (p = 0.024 and p = 0.021), while
higher histological grade was more frequent in patients
with available blocks only in the HE10/00 trial (p = 0.026).
Incidence and associations between examined biological
markers
Representative FISH images for HER2, TOP2A and
CEP17 are shown in Figure 2. The distribution of
centrally assessed tumor markers by FISH and IHC are
presented in Table 2. Cases with HER2 deletions (n = 27,
2.6%) were grouped together with HER2 normal tumors,
for analysis purposes. Amplification, classified according
to gene/CEP17 ratios, was found for HER2 in 23.7% and
for TOP2A in 10.1% of the tumors. The incidence of
amplified tumors was lower when amplification was con-
sidered according to the cut-off of >6 copies for each
gene (Table 2). Ten cases were equivocal for HER2 (with
HER2/CEP17 ratios between 1.8-2.2 and ≤6 gene copies)
and they were also included in the HER2 normal tumors,
for analysis purposes. CEP17 gain was seen in approxi-
mately 40% of tumors (Table 2). Histograms of the dis-
tribution of HER2, TOP2A and CEP17 copy numbers are
presented in Figure 3.
Examining the association of markers with clinico-
pathological parameters, CEP17 gene gain was found to
be associated only with postmenopausal status (48.1% in
no gain vs. 60.6% in gain, p < 0.001) (Additional file 1:
Table S2). HER2 gene amplification was associated with
higher histological grade (45% in non-amplified vs. 66%
in amplified, p < 0.001), ductal carcinoma (75% in non-
amplified vs. 87% in amplified, p < 0.001), negative
receptor status (16% in non-amplified vs. 44% in ampli-
fied, p < 0.001) and high Ki67 (64% in non-amplified vs.
79% in amplified, p < 0.001), while TOP2A amplification
was associated with higher histological grade (58% in
deleted vs. 49% in non-amplified vs. 62% in amplified,
p = 0.023) and negative receptor status (37% in deleted vs.
20% in non-amplified vs. 40% in amplified, p < 0.001).
Overall, 24% of the patients had a HER2-positive sta-
tus, based on either HER2 gene/CEP17 ratio of >2.2 or
gene copy number of >6 or an IHC score of 3+. Interest-
ingly, 27 tumors with HER2 IHC scores of 0 (7 cases) or
1+ (20 cases), were found to be amplified either by gene
gain >6 (n = 3) or FISH ratio >2.2 (n = 24) (Additional
file 1: Table S3). In addition, among cases with HER2
IHC scores of 0 or 1+, there were 17 tumors (2.4%) with
HER2 deletion. It is worth noting that among 204 cases
with HER2/CEP17 ratio >2.2 (i.e., amplified by ratio
criteria), 184 (90%) also had >6 HER2 gene copies (i.e.,
amplified by gene copy criteria).
Figure 2 Representative FISH images in invasive breast carcinoma (IBC) cases, using the HER2/TOP2A/CEP17 triple-color probes. In the
first four panels (A-D) an IBC case is shown with normal status of the HER2 gene (A), TOP2A gene (B) and CEP17 (C). An IBC case (E-H) showing
simultaneous amplification of the HER2 and TOP2A genes (E-F), as well as CEP17 gain (G). The third IBC case presented in panels (I-L) showed
amplification of the HER2 gene (I), normal status of the TOP2A gene (J) and CEP17 gain (K). In the last case, co-amplification of the HER2 (M) and
TOP2A genes (N) was found in tumor cells, accompanied by high-level CEP17 gain (O). The last panel for each case (panels D, H, L and P) depicts
a merged image of the three-colored probes. Magnification x1000. CEP17, centromere 17 enumeration probe.
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about one third of the cases (N = 120), while they were
TOP2A amplified in 15% of the cases (N = 59) (Table 3).
Among 244 HER2 amplified tumors, 51% had CEP17
gain. Similar percentages were observed for CEP17 gain
in TOP2A amplified (58%) and deleted tumors (65%).
Overall, tumors with low HER2 or TOP2A copy num-
bers had CEP17 gain in 37% and 36%, respectively
(Table 3). In addition, among 827 tumors with HER2/
CEP17 ratio ≤2.2, 327 (40%) had CEP17 gain. Among 10
equivocal cases with HER2/CEP17 ratios between 1.8-2.2
there was only one case with CEP17 gain.
The distribution of TOP2A and CEP17 by breast cancer
tumor subtypes is presented in Table 4. Among 126 triple-
negative breast cancer (TNBC) tumors, no amplificationsof TOP2A were found. CEP17 gain was more frequent in
Luminal-HER2 and HER2-enriched tumors.
Associations of TOP2A gene status and TopoIIa protein
expression are shown in detail (Additional file 1: Table
S4). TOP2A deletions did not result in lower TopoIIa ex-
pression. Among 953 cases with paired TOP2A gene sta-
tus and protein expression data, there were 28 tumors
with TOP2A gene deletion and simultaneous protein ex-
pression. No association was found between TopoIIa pro-
tein expression and TOP2A gene amplification (p = 0.22).
Significant associations were observed between CEP17
gene status and HER2 protein expression, as well as
TopoIIa protein expression (Additional file 1: Table S5).
More specifically, CEP17 gain was more frequent in HER2
2+ and 3+ tumors and in tumors expressing TopoIIa.
Table 2 Distribution of centrally assessed tumor markers
by FISH and IHC
N (%)
FISH CEP17 status (n = 1031)
Median (range) 2.00 (0.70-26.55)
No gain 620 (60.1)
Gain 411 (39.9)
HER2 (gene copies) (n = 1031)
Median (range) 2.55 (0.70-45.15)
Low normal-replicated (≤4) 742 (72.0)
Low gain (4–6) 65 (6.3)
High gain (>6) 224 (21.7)
HER2 gene status (n = 1031)
Non-amplified1 787 (76.3)
Amplified2 244 (23.7)
TOP2A (gene copies) (n = 1031)
Median (range) 2.15 (0.70-26.15)
Low normal-replicated (≤4) 875 (84.9)
Low gain (4–6) 77 (7.5)
High gain (>6) 79 (7.7)









TopoIIa (n = 953)
Negative 441 (46.3)
Positive 512 (53.7)
ER (n = 1018)
Negative 272 (26.7)
Positive 746 (73.3)
PgR (n = 1024)
Negative 335 (32.7)
Positive 689 (67.3)
Ki67 (n = 1000)
Low 322 (32.2)
High 678 (67.8)
127 cases (2.6%) had a deletion with a HER2/CEP17 ratio <0.8.
2204 cases (83.6%) with HER2/CEP17 ratio >2.2 and 40 cases (16.4%) with HER2
gene gain (>6 copies).
364 cases (61.5%) with TOP2A/CEP17 ratio ≥2.0 and 40 cases (38.5%) with
TOP2A gene gain (>6 copies).
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TOP2A co-amplification (Additional file 1: Table S6).
Among the HER2 non-amplified cases, 28 deletions
(3.6%) and only two amplifications of the TOP2A gene
were identified.
Associations of examined markers with prognosis
DFS and OS did not differ significantly between treat-
ment groups. At a median follow-up of 106 months
(range 0.1-167), the 5-year DFS rates were 75%, 69% and
75%, while the OS rates were 88%, 81% and 86%, for the
E-T-CMF, E-CMF and ET-CMF groups, respectively
(Additional file 1: Table S7).
HER2 amplification, TOP2A amplification, TopoIIa
protein expression, CEP17 gain and HER2/TOP2A co-
amplification were not associated with either relapse or
death (Figures 4, 5, 6 and 7). Similarly, when examining
combined TOP2A gene pathology (deletion and amplifi-
cation) vs. normal TOP2A, no effect on patient outcome
was observed. This did not change when adjusting for
treatment group in the Cox regression model. HER2 and
TOP2A gene copy numbers (amplified vs. low gain vs.
low-normal-replicated) were also not associated with
DFS or OS. Stratifying by CEP17 status, differences in
outcome by HER2 gene status (amplified vs. non-
amplified tumors) and by TOP2A gene status (amplified
vs. deleted vs. non-amplified tumors) were examined.
No such differences were observed for either DFS or OS.
The predictive role of all examined markers for pacli-
taxel treatment were also evaluated, performing Cox
model analysis with interaction terms of each gene with
treatment (paclitaxel vs. no paclitaxel). None of the
markers tested was predictive for paclitaxel treatment.
Multivariate analyses for the examined biological
markers, in the presence of significant clinical parame-
ters and treatment group, are presented by forest plots
(Figure 8). Clinicopathological factors associated with in-
creased risk for both relapse and death were tumor size
of more than 5 cm (p = 0.009 for DFS and p = 0.001 for
OS) and four or more positive nodes (p < 0.001 for both
DFS and OS). Hormonal therapy was associated with
improved DFS and OS (p = 0.028 and p = 0.002, respect-
ively), while breast-conserving surgery was associated
with improved DFS only (p = 0.011) and high histological
grade with poor OS only (p = 0.039). No association was
found with DFS or OS for any of the examined chromo-
some 17 markers. Finally, none of the examined markers
were associated with either DFS or OS in the context of
univariate or multivariate analyses, when excluding the
lymph node samples.
Discussion
In the present study we investigated the prognostic role







































Figure 3 Distribution of HER2, TOP2A and CEP17 copies (A, B and C). Red line represents 6 gene copies (for A and B) and 3 copies for C.
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http://www.biomedcentral.com/1471-2407/13/163status and protein expression in 1031 patients with oper-
able breast cancer. All these patients were treated with
epirubicin-based adjuvant chemotherapy in the context
of two consecutively conducted phase III trials [39-41].
In a previous study published by our group for theTable 3 CEP17 status according to HER2 and TOP2A gene
copy number and amplification status
CEP17 status
No gain Gain
N (%) N (%) p
HER2 gene copies <0.001
≤4 506 (68.2) 236 (31.8)
4-6 10 (15.4) 55 (84.6)
>6 104 (46.4) 120 (53.6)
TOP2A gene copies <0.001
≤4 587 (67.1) 288 (32.9)
4-6 13 (16.9) 64 (83.1)
>6 20 (25.3) 59 (74.7)
HER2 gene status <0.001
Non-amplified 500 (63.5) 287 (36.5)
Amplified 120 (49.2) 124 (50.8)
TOP2A gene status <0.001
Deleted 18 (34.6) 34 (65.4)
Non-amplified 558 (63.8) 317 (36.2)
Amplified 44 (42.3) 60 (57.7)HE10/00 and HE10/97 cohorts [42], patients with either
luminal B, luminal-HER2 or HER2-enriched tumors
performed worse than those with luminal A tumors, while
patients with triple-negative tumors had the worst out-
come. In addition, it was observed that the HER2-enriched
subtype was predictive of response to paclitaxel-containing
treatments. These prognostic and predictive HER2-related
effects were breast cancer subtype specific and were not
maintained in the present study. An earlier observation
reported for this cohort, of HER2 amplification being pre-
dictive for OS benefit from adjuvant treatment with pacli-
taxel [56], was not confirmed in the current analysis with
updated follow-up. In both analyses however, the ability to
detect any predictive impact of HER2/TOP2A amplification
or CEP17 gain in the presence of taxanes was limited (only
1 of the 4 trial arms did not include taxanes). The present
results concerning HER2 are in line with reports on the
prognostic value of this marker [59,60]. A recent meta-
analysis suggests that patients with both HER2 amplified
and non-amplified tumors may benefit from anthracyclines
[61,62]. This could not be investigated in the current study,
since all patients had been treated with anthracyclines.
Among HER2 amplified tumors, 42% exhibited TOP2A
co-amplification, which is within the reported range of
35%-50% for this genomic alteration [26,29,63,64]. TOP2A
deletions were more common in HER2 amplified tumors,
comprising approximately 10% of the HER2 amplified
cases. TOP2A gene pathology (amplification, deletion and
combinations of both) has been reported as a favorable
Table 4 HER2, TOP2A and CEP17 status and TopoIIa protein expression according to breast cancer subtypes defined by
immunohistochemistry
Luminal A Luminal B Luminal-HER2 HER2-enriched TNBC
N (%) N (%) N (%) N (%) N (%)
FISH
HER2 gene status
Non-amplified 242 (100.0) 386 (100.0) 3 (2.2) 1 (0.9) 126 (100.0)
Amplified 0 0 135 (97.8) 107 (99.1) 0
TOP2A gene status
Deleted 5 (2.1) 15 (3.9) 12 (8.7) 11 (10.2) 8 (6.3)
Non-amplified 236 (97.5) 371 (96.1) 65 (47.1) 55 (50.9) 118 (93.7)
Amplified 1 (0.4) 0 61 (44.2) 42 (38.9) 0
CEP17 status
No gain 149 (61.6) 234 (60.6) 70 (50.7) 50 (46.3) 93 (73.8)
Gain 93 (38.4) 152 (39.4) 68 (49.3) 58 (53.7) 33 (26.2)
IHC
TopoIIa
Negative 165 (73.7) 130 (35.2) 48 (36.9) 43 (41.7) 49 (42.6)
Positive 59 (26.3) 239 (64.8) 82 (63.1) 60 (58.3) 66 (57.4)
TNBC, triple-negative breast cancer.
Patients were classified as: luminal A (ER-positive and/or PgR-positive, HER2-negative, Ki67low); luminal B (ER-positive and/or PgR-positive, HER2-negative, Ki67high);
luminal-HER2 (ER-positive and/or PgR-positive, HER2-positive); HER2-enriched (ER-negative, PgR-negative, HER2-positive); and TNBC (ER-negative, PgR-negative,
HER2-negative).
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http://www.biomedcentral.com/1471-2407/13/163prognostic and predictive marker in adjuvant-treated
breast cancer patients [36,65]. However, in the present
study we did not observe any association between patient
outcome and TOP2A amplification, deletion, or both, in
accordance with the recent meta-analysis mentioned
above [62].
The clinical importance of CEP17 gain, as detected by
FISH, in human breast cancer remains a controversial
issue. From the biological perspective, CEP17 gain and
chromosome 17 polysomy do not represent the sameFigure 4 Kaplan-Meier curves for DFS and OS according to HER2 gensituation, since the first one corresponds to the fluorescent
signals of a 5.6 kb region, while the second reflects aber-
rant numbers of the whole chromosome, which should be
demonstrated with spectral karyotyping (SKY) or other
cytogenetic approaches. The CEP17 FISH probe detects
the alpha-satellite repeat region at the centromere of
chromosome 17, at 17p11.1-17q11.1. The specificity of
CEP17 remains undetermined, while this probe and a
centromeric probe detecting additional neighboring re-
gions on 17p11.2-12 yield different results concerninge status (log-rank test p-values).
Figure 5 Kaplan-Meier curves for DFS and OS according to TOP2A gene status (log-rank test p-values).
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http://www.biomedcentral.com/1471-2407/13/163chromosome 17 status and, therefore, different HER2 gene
amplification status, when the latter is assessed as HER2/
CEP17 ratio of >2.2 [66]. This may reflect the presence of
the probed satellite repeats outside the centromeric re-
gion, which happen during evolution [67] and probably
during cancer clone evolution, as well. Another problem
for assessing low copy gains is that during DNA synthesis
and in the G2/M phases, the targeted regions will appear
double (three to four copies instead of two, taking into ac-
count the nuclear truncation effect during paraffin block
sectioning). The cut-off used in the present study for the
classification of CEP17 gains has been shown to correct
for the maximally four centromeric signals that would be
expected in this situation [55]. With this cut-off, we
detected CEP17 gain in approximately 40% of all carcin-
omas examined, which is in the range of published results
when using the FISH method in all-type breast carcinoma
series (10-50%) [12-14,54,68,69].Figure 6 Kaplan-Meier curves for DFS and OS according to CEP17 gaiMeasurement of CEP17 probe signals reflects the con-
dition of the corresponding centromeric area and can by
no means reflect gains of the entire chromosome 17 or
“chromosome 17 polysomy”, as often reported in the lit-
erature. In the same treatment settings, depending on
how CEP17 signals are classified and interpreted, and
also depending on the drugs administered, the effect of
CEP17 status on patient outcome may vary. Thus, in the
adjuvant setting, by using the same FISH probe, duplica-
tion of the CEP17 region of chromosome 17 seems to be
predictive of benefit from anthracyclines [22,70] or of
borderline association with clinical response to the same
drugs [71]. Furthermore, CEP17 gain in the absence of
HER2/TOP2A amplification has been reported by one
recent study to be an unfavorable prognostic marker
[72]; however, no prognostic value was identified for
CEP17 gain in other studies [55,64,69], which is in line
with our present findings.n (log-rank test p-values).
Figure 7 Kaplan-Meier curves for DFS and OS according to HER2/TOP2A co-amplification (log-rank test p-values).
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http://www.biomedcentral.com/1471-2407/13/163CEP17 appears to be related with disease prognosis
when this marker is combined with HER2 status. Whether
“polysomy” 17 drives HER2 amplification or the opposite
is true, as was recently suggested [54,73], remains un-
answered; it is, however, noteworthy that “polysomy” 17 is
rarely observed in circulating tumor cells from patients
with metastatic breast cancer and when present, itFigure 8 Multivariate analyses presented by forest plots in terms of Dcorresponds to HER2-negative primary tumors [74]. In
the absence of HER2 amplification, CEP17 “polysomy” has
been reported to confer a more favorable prognosis [75]
or to be associated with aggravating prognostic markers
[76]. In addition to these contradictory results, herein we
did not observe any interaction between CEP17 and HER2
status. Methodological differences in the assessment ofFS (A) and OS (B).
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http://www.biomedcentral.com/1471-2407/13/163these parameters and cohort-fitted results should account
for the diversity of data regarding the role of CEP17/HER2
status on adjuvant-treated breast cancer patients.
Although more than half of the tumors with CEP17 gain
were not HER2 or TOP2A amplified, we did observe a
higher than double incidence of CEP17 gain in tumors
with aberrant HER2 and TOP2A genes (amplification, de-
letion, and, especially, high copy gains) in comparison to
tumors with a normal status of these genes. These data
are in line with “polysomy” 17 correlating with multiple
copies of HER2 but not with HER2 amplification [77],
while they further justify the higher incidence of CEP17
gain in the luminal-HER2 and HER2-enriched subtypes,
as described in this study.
Equivocal HER2 IHC findings were observed in cases
with chromosome 17 “polysomy” and correspondingly
increased HER2 gene copy numbers [54,78]. In the
present study, the incidence of CEP17 gains was strongly
related to HER2 IHC grades, but it did not contribute to
the further assessment of HER2 IHC 2+ cases. With re-
spect to FISH equivocal cases, herein we used very strin-
gent criteria involving both gene/CEP17 ratios and gene
copy numbers. Increased CEP17 ratios might result in
false negative HER2/CEP17 ratios of ≤2.2; on the other
hand, their coincidence with increased HER2 copies is
not equivalent to HER2-positive disease [79]. The few
(n = 10, <0.01% of the entire tumor series) FISH equivo-
cal tumors for HER2 gene status were HER2 IHC 0 to 2+.
CEP17 gain was observed in only one such case. Hence, at
least in the present series, CEP17 gain did not aid further
in the classification of equivocal HER2 gene status cases.
In addition, we observed that most of the tumors with
low-gain of HER2 and/or TOP2A copies indeed had
CEP17 gains as well. However, in order to evaluate the im-
pact of these concomitant alterations on patient outcome,
larger patient series with this sub-category of tumors
would be needed.
Conclusions
The present combined chromosome 17 marker analysis by
FISH represents one of the largest of its type in early high-
risk breast cancer. With the cut-offs used for the
characterization of CEP17 gain, as well as HER2 and
TOP2A gene amplification, these chromosome 17 markers,
individually or in conjunction, did not appear to be related
with patient outcome.
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